Nothing is going any more between Bastide Médical, and Bpifrance, minority shareholder of SIB, the holding of control (unlisted) of this company of 3000 employees.
At the origin of the conflict: the desire of Bastide Médical, specialist in home health care (oxygen therapy, diabetes, etc.) and distributor of medical devices, to leave compartment B of Euronext to join Euronext Growth in 2021.
This change has been adopted by many companies this year (Fleury Michon, Euromedis, etc.) because the Growth compartment generates fewer obligations for companies.
On the other hand, it is less popular with institutional investors, which raises concerns that the securities transferred will drop.
"The way Growth works is more suited to the size and current needs of the group, while allowing it to continue to benefit from the attractiveness of the financial markets at a more reasonable cost"
, explains Vincent Bastide, CEO of the group who realized 382 million euros in turnover
This article is for subscribers only.
You have 67% left to discover.
Subscribe: 1 € the first month
Can be canceled at any time
I ENJOY IT
Already subscribed?
Log in